

## SLE, hydroxychloroquine and no SLE patients with covid-19: a comment

Inter-relationship between covid-19 and rheumatic diseases is an interesting topic in clinical rheumatology. We found that article ‘Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies’ is informative. Monti *et al* suggested for ‘avoiding the unjustifiable preventive withdrawal of DMARDs, which could lead to an increased risk of relapses and morbidity from the chronic rheumatological condition’.<sup>1</sup> Whether standard therapy for rheumatic diseases have any effect on clinical course of covid-19 is an interesting issue. Clinically, co-occurrence between covid-19 and other medical disorder is an interesting situation. We hereby would like to draw attention to a specific disease that is little mentioned, systemic lupus erythematosus (SLE). SLE is a common immunological disorder that is seen worldwide. There are several thousands of patients with covid-19 worldwide. Nevertheless, there is no case of SLE with covid-19. In fact, a similar unusual clinical observation is already mentioned on covid-19 and HIV infection.<sup>1</sup> HIV-infected patients who intake anti-HIV drug might have lower risk to get covid-19 than general population since anti-HIV drug is proven for efficacy against the novel coronavirus.<sup>2</sup> Regarding SLE, hydroxychloroquine is a widely used drug for treatment.<sup>3</sup> Hydroxychloroquine is also reported for efficacy against covid-19.<sup>4</sup>

Hence, hydroxychloroquine use might be an explanation for no report on SLE patient with covid-19. This is an example that can support the suggestion of Monti *et al* on medication for rheumatic diseases in the present covid-19 crisis.

Beuy Joob ,<sup>1</sup> Viroj Wiwanitkit<sup>2</sup>

<sup>1</sup>Medical Center, Sanitation 1 Medical Academic Center, Bangkok, Thailand

<sup>2</sup>Department of Community Medicine, Dr DY Patil University, Pune, Maharashtra, India

**Correspondence to** Dr Beuy Joob, Sanitation 1 Medical Academic Center, Bangkok 10140, Thailand; beuyjoob@hotmail.com

**Contributors** BJ and VW equally contributed to the work and approved for final submission.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Joob B, Wiwanitkit V. *Ann Rheum Dis* Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-217506

Received 3 April 2020

Accepted 6 April 2020

*Ann Rheum Dis* 2020;**0**:1. doi:10.1136/annrheumdis-2020-217506

### ORCID iD

Beuy Joob <http://orcid.org/0000-0002-5281-0369>

### REFERENCES

- 1 Monti S, Balduzzi S, Delvino P, *et al*. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis* 2020:annrheumdis-2020-217424.
- 2 Joob B, Wiwanitkit V. SARS-CoV-2 and HIV. *J Med Virol* 2020. doi:10.1002/jmv.25782. [Epub ahead of print: 27 Mar 2020].
- 3 Yasri S, Wiwanitkit V. Dose prediction of lopinavir/ritonavir for 2019-novel coronavirus (2019-nCoV) infection based on mathematic modeling. *Asian Pac J Trop Med* 2020;13:137–8. -.
- 4 Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). *Expert Opin Drug Saf* 2017;16:411–9.